Targeting B cells to modify MS, NMOSD, and MOGAD
Open Access
- 1 January 2021
- journal article
- review article
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 8 (1)
Abstract
Ocrelizumab, rituximab, ofatumumab, ublituximab, inebilizumab, and evobrutinib are immunotherapies that target various B cell–related proteins. Most of these treatments have proven efficacy in relapsing and progressive forms of MS and neuromyelitis optica spectrum disease (NMOSD) or are in advanced stages of clinical development. Currently, ocrelizumab and inebilizumab are licensed for treatment of MS and NMOSD, respectively. This part of the review focuses on monoclonal antibody B cell–depleting strategies in NMOSD and the emerging related myelin oligodendrocyte glycoprotein (MOG) immunoglobulin G–associated disease (MOGAD). Case series and phase 2/3 studies in these inflammatory disorders are assessed. The safety profile of long-term B-cell depletion in MS, NMOSD, and MOGAD will be highlighted. Finally implications of the current coronavirus disease 2019 pandemic on the management of patients with these disorders and the use of B cell–depleting agents will be discussed.Keywords
This publication has 57 references indexed in Scilit:
- Disease-modifying therapies and infectious risks in multiple sclerosisNature Reviews Neurology, 2016
- Rituximab does not reset defective early B cell tolerance checkpointsJournal of Clinical Investigation, 2015
- Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 YearsThe Journal of Rheumatology, 2015
- Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patientsMultiple Sclerosis Journal, 2015
- B lymphocytes in neuromyelitis opticaNeurology Neuroimmunology & Neuroinflammation, 2015
- CD19 as a molecular target in CNS autoimmunityActa Neuropathologica, 2014
- Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)Journal of Neurology, 2013
- A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum DisorderJAMA Neurology, 2013
- A glycoengineered anti‐CD19 antibody with potent antibody‐dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivoBritish Journal of Haematology, 2011
- B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 AntibodyThe Journal of Pharmacology and Experimental Therapeutics, 2010